| EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib S Kobayashi, TJ Boggon, T Dayaram, PA Jänne, O Kocher, M Meyerson, ... New England Journal of Medicine 352 (8), 786-792, 2005 | 4876 | 2005 |
| Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer L Paz-Ares, A Luft, D Vicente, A Tafreshi, M Gümüş, J Mazières, B Hermes, ... New England journal of medicine 379 (21), 2040-2051, 2018 | 3525 | 2018 |
| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2840 | 2019 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1963 | 2020 |
| Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ... Science translational medicine 4 (120), 120ra17-120ra17, 2012 | 1512 | 2012 |
| Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Z Zhang, JC Lee, L Lin, V Olivas, V Au, T LaFramboise, M Abdel-Rahman, ... Nature genetics 44 (8), 852-860, 2012 | 1325 | 2012 |
| Case fatality rate of cancer patients with COVID-19 in a New York hospital system V Mehta, S Goel, R Kabarriti, D Cole, M Goldfinger, A Acuna-Villaorduna, ... Cancer discovery 10 (7), 935-941, 2020 | 820 | 2020 |
| Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or erlotinib DM Jackman, BY Yeap, LV Sequist, N Lindeman, AJ Holmes, VA Joshi, ... Clinical Cancer Research 12 (13), 3908-3914, 2006 | 715 | 2006 |
| Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia M Bentires-Alj, JG Paez, FS David, H Keilhack, B Halmos, K Naoki, ... Cancer research 64 (24), 8816-8820, 2004 | 628 | 2004 |
| A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407 L Paz-Ares, D Vicente, A Tafreshi, A Robinson, HS Parra, J Mazières, ... Journal of Thoracic Oncology 15 (10), 1657-1669, 2020 | 623 | 2020 |
| BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations DB Costa, B Halmos, A Kumar, ST Schumer, MS Huberman, TJ Boggon, ... PLoS medicine 4 (10), e315, 2007 | 580 | 2007 |
| Structure and clinical relevance of the epidermal growth factor receptor in human cancer A Kumar, ET Petri, B Halmos, TJ Boggon Journal of Clinical Oncology 26 (10), 1742-1751, 2008 | 470 | 2008 |
| Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ... Journal of Thoracic Oncology 11 (9), 1493-1502, 2016 | 417 | 2016 |
| Differential effects of gefitinib and cetuximab on non–small-cell lung cancers bearing epidermal growth factor receptor mutations T Mukohara, JA Engelman, NH Hanna, BY Yeap, S Kobayashi, ... Journal of the National Cancer Institute 97 (16), 1185-1194, 2005 | 407 | 2005 |
| Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance GN Naumov, MB Nilsson, T Cascone, A Briggs, O Straume, LA Akslen, ... Clinical Cancer Research 15 (10), 3484-3494, 2009 | 393 | 2009 |
| Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations X Liu, Y Jia, MB Stoopler, Y Shen, H Cheng, J Chen, M Mansukhani, ... Journal of clinical oncology 34 (8), 794-802, 2016 | 374 | 2016 |
| Seroconversion rates following COVID-19 vaccination among patients with cancer A Thakkar, JD Gonzalez-Lugo, N Goradia, R Gali, LC Shapiro, K Pradhan, ... Cancer cell 39 (8), 1081-1090. e2, 2021 | 355 | 2021 |
| An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor S Kobayashi, H Ji, Y Yuza, M Meyerson, KK Wong, DG Tenen, B Halmos Cancer research 65 (16), 7096-7101, 2005 | 322 | 2005 |
| Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study S Novello, DM Kowalski, A Luft, M Gümüş, D Vicente, J Mazières, ... Journal of Clinical Oncology 41 (11), 1999-2006, 2023 | 286 | 2023 |
| Dysregulation of the C/EBPα differentiation pathway in human cancer S Koschmieder, B Halmos, E Levantini, DG Tenen Journal of Clinical Oncology 27 (4), 619-628, 2009 | 280 | 2009 |